North American Vaccine Inc.The Beltsville vaccine...

BY THE NUMBERS

May 08, 1992

North American Vaccine Inc.

The Beltsville vaccine development company said its losses in the quarter that ended March 30 doubled, to $2 million, compared with the same period last year.

The research and development company attributed much of the loss to legal fees associated with a patent-infringement suit the company filed last year against American Cyanamid Co. of New Jersey. The case will go to trial in August.

The company's revenues come from its sale of a pertussis vaccine to the National Institutes of Health, which is using it to test the vaccine's effectiveness and safety in children. Preliminary results of the tests look promising, the company said.

Three months ended 3/31/92

.. .. .. Revenue.. .. .. .. .. .. Net.. .. .. .. .. .. Share

'92.. .. 475,000.. .. .. .. .. .. (2,046,000).. .. .. (.08)

'91.. .. .609,000.. .. .. .. .. .. (1,021,000).. .. .. (.05)

% change.. .. -22.0.. .. .. .. .. .. --.. .. .. .. .. .. --

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.